机构

• 上海药物研究所 [20]
• 合肥物质科学研究院 [15]
• 自动化研究所 [6]
• 过程工程研究所 [2]
• 水生生物研究所 [1]
• 近代物理研究所 [1]
• 更多

采集方式

• OAI收割 [46]

内容类型

• 期刊论文 [45]
• 专著章节 [1]

发表日期

• 2023 [5]
• 2022 [15]
• 2021 [10]
• 2020 [8]
• 2019 [6]
• 2018 [2]
• 更多

学科主题

筛选

浏览/检索结果: 共46条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2023, 卷号: 13, 期号: 12, 页码: 4748-4764 作者:  Liu, Yingqiang;  Zhan, Zhengsheng;  Kang, Zhuang;  Li, Mengyuan;  Lv, Yongcong   |  收藏  |  浏览/下载：9/0  |  提交时间：2024/01/26 Small molecule inhibitor  Tumor microenvironment  Immune-checkpoint  immune-deficient mouse models  including temozolomide (TMZ) insensitive tumors. Notably   Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors 期刊论文  OAI收割 BIOORGANIC CHEMISTRY, 2023, 卷号: 140, 页码: 18 作者:  Zhang, Junjie;  Li, Yan;  Tang, Haotian;  Zhou, Qianqian;  Tong, Linjiang   |  收藏  |  浏览/下载：8/0  |  提交时间：2023/12/08 Cancer immunotherapy  HPK1  Structure -based design  HPK1 inhibitor   Breaking Tumor Immunosuppressive Network by Regulating Multiple Nodes with Triadic Drug Delivery Nanoparticles 期刊论文  OAI收割 ACS NANO, 2023, 卷号: 17, 期号: 18, 页码: 17826-17844 作者:  Yan, Wenlu;  Li, Yu;  Zou, Yiting;  Zhu, Runqi;  Wu, Ting   |  收藏  |  浏览/下载：8/0  |  提交时间：2023/12/08 triple-negative breast cancer  antitumor immunity  tumor-associated macrophages  myeloid-derived suppressorcells  immune network  nanoparticle   Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression 期刊论文  OAI收割 JOURNAL OF CLINICAL INVESTIGATION, 2023, 卷号: 133, 期号: 9, 页码: 12 作者:  Wang, Xiaobo;  Huang, Jing;  Liu, Fenglin;  Yu, Qian;  Wang, Ruina   |  收藏  |  浏览/下载：19/0  |  提交时间：2023/10/17 Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 12, 页码: 2315-2328 作者:  Luo, LingJie;  Lin, Caiji;  Wang, Pengfei;  Cao, Danli;  Lin, Yiru   |  收藏  |  浏览/下载：11/0  |  提交时间：2023/10/17 Immune checkpoint inhibitor  Phytochemicals  Combination therapy  Immune-related adverse events  Predictive biomarker  Gut microbiota   Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors 期刊论文  OAI收割 BMC Medicine, 2022, 卷号: 20, 期号: 1 作者:  Zhang,Pei;  Du,Yang;  Bai,Hua;  Wang,Zhijie;  Duan,Jianchun   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/11/21 Tucidinostat  Tumor microenvironment  PD-L1  CCL5  Solid tumor   Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor 期刊论文  OAI收割 THORACIC CANCER, 2022 作者:  Wang, Wenxian;  Wang, Qian;  Xu, Chunwei;  Li, Ziming;  Song, Zhengbo   |  收藏  |  浏览/下载：37/0  |  提交时间：2022/12/23 checkpoint inhibitor pneumonitis  Chinese experts consensus  immune checkpoint inhibitor-related adverse effects   Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety 期刊论文  OAI收割 JOURNAL OF THORACIC DISEASE, 2022 作者:  Shao, Lan;  Lou, Guangyuan   |  收藏  |  浏览/下载：19/0  |  提交时间：2022/12/22 Neoadjuvant  immunotherapy  immune-checkpoint inhibitors  non-small cell lung cancer (NSCLC)   The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study 期刊论文  OAI收割 CANCERS, 2022, 卷号: 14 作者:  Xie, Mingying;  Li, Na;  Xu, Xiaoling;  Xu, Yanjun;  Li, Hui   |  收藏  |  浏览/下载：21/0  |  提交时间：2022/12/22 liver metastasis  non-small cell lung cancer  PD-L1  PD-1  PD-L1 inhibitor  CD8+T cell   Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer 期刊论文  OAI收割 ACTA PHARMACEUTICA SINICA B, 2022, 卷号: 12, 期号: 9, 页码: 3726-3738 作者:  Zheng, Chao;  Zhang, Wen;  Wang, Jinming;  Zhai, Yihui;  Xiong, Fengqin   |  收藏  |  浏览/下载：34/0  |  提交时间：2022/12/13 KEY WORDS High-density lipoprotein  Immunotherapy  Combination therapy  Metastasis  Triple-negative breast cancer  Lenvatinib  Vadimezan  Immune checkpoint blockade